Trials / Completed
CompletedNCT00997919
A Study of the Safety, Tolerability, Pharmacokinetics, and Bioavailability of IV and SC MABT5102A in Healthy Volunteers
A Phase I, Single-Dose, Randomized, Parallel-Group, Open-Label Study of the Safety, Tolerability, Pharmacokinetics, and Bioavailability of IV and SC MABT5102A in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 22 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
This Phase I, single-dose, randomized, parallel-group, open-label study will evaluate the safety, tolerability, and pharmacokinetics of MABT5102A following subcutaneous (SC) and intravenous (IV) administration in healthy volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MABT5102A | single SC dose |
| DRUG | MABT5102A | single IV dose |
Timeline
- Start date
- 2009-10-01
- Primary completion
- 2010-02-01
- Completion
- 2010-02-01
- First posted
- 2009-10-20
- Last updated
- 2017-05-30
Source: ClinicalTrials.gov record NCT00997919. Inclusion in this directory is not an endorsement.